Based on the findings of the present study, it is recommended that EGFR mutation testing be routinely performed for all patients diagnosed with NSCLC regardless of gender and smoking history considering that EGFR mutations were identified in a significant proportion (25.3%) of patients with lung adenocarcinoma and also it can still occur in nonsmokers and light smokers. This evidence concerns the gene EGFR and lung adenocarcinoma.